The study included all patients aged ≥18 years, who were identified from SIA/SUS database, received SGAs (clozapine, olanzapine, quetiapine, risperidone, or ziprasidone) for more than 90 days, during January 2008 to December 2017, and diagnosed with one of the following diseases according to International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10): Paranoid schizophrenia (F20.0), Hebephrenic schizophrenia (F20.1), Catatonic schizophrenia (F20.2), Undifferentiated schizophrenia (F20.3), Post-schizophrenic depression (F20.4), Residual schizophrenia (F20.5), Simple schizophrenia (F20.6), Other schizophrenia (F20.8), Schizoaffective disorder, manic type (F25.0), Schizoaffective disorder, depressive type (F25.1), Schizoaffective disorder, depressive type (F25.2).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.